Latest Tax Rebates News

Page 3 of 16
Anson Resources has locked in a substantial $194 million business incentive from the Utah Inland Port Authority to support its Green River Lithium Project, underpinning the financing of its planned 10,000tpa lithium carbonate plant.
Maxwell Dee
Maxwell Dee
4 Sept 2026
Nexalis Therapeutics reports a 52% rise in half-year losses to $1.3 million amid funding facility cancellation and clinical trial suspensions, highlighting ongoing cash flow challenges.
Ada Torres
Ada Torres
1 Sept 2026
Wide Open Agriculture cut its loss to $3.64 million in FY2026 as it pivots from owning manufacturing to a capital-light contract model, while securing global commercial traction for its lupin-based ingredients.
Ada Torres
Ada Torres
31 Aug 2026
Actinogen Medical reported a $15.38 million loss for FY2026 while progressing its lead Alzheimer's drug Xanamem toward pivotal trial results expected this November. The company secured regulatory alignment and strengthened its cash position to fund operations through mid-2027.
Ada Torres
Ada Torres
27 Aug 2026
EMVision Medical Devices has made significant strides in its emu™ bedside scanner pivotal trial and First Responder program, boosting FY26 revenue by 57% while trimming its net loss by 15%.
Ada Torres
Ada Torres
24 Aug 2026
PlaySide Studios reversed a prior-year loss with a 13% revenue increase to $54.9 million and a 144% jump in net profit to $5.4 million, driven by strong Original IP sales and a strategic cost restructure.
Sophie Babbage
Sophie Babbage
20 Aug 2026
ReNerve Limited delivered its strongest sales quarter ever with $211,000 in revenue, boosted by new distribution deals in Asia-Pacific and a $5 million funding facility to underpin growth.
Ada Torres
Ada Torres
29 July 2026
Wide Open Agriculture (ASX: WOA) is executing a major strategic pivot by closing its German production site and transitioning to a capital-light contract manufacturing model to improve economics and scale lupin protein production.
Ada Torres
Ada Torres
28 July 2026
Nyrada has dosed the first patient in its Phase IIa trial of Xolatryp targeting heart attack recovery, while strengthening its cash reserves and receiving a US patent allowance for its lead drug.
Ada Torres
Ada Torres
27 July 2026
Biotron has received pivotal regulatory feedback from the European Medicines Agency ruling out a Hybrid Marketing Authorisation for SedRx, prompting plans for pivotal clinical trials. The company also advances its lead antiviral candidate BIT-HBV001 against Hepatitis Delta Virus and appoints a new chairman.
Ada Torres
Ada Torres
21 July 2026
Impact Minerals (ASX:IPT) has received a $310,000 Research and Development tax rebate for FY2025, supporting its Lake Hope High Purity Alumina project and investment in Alluminous Pty Ltd.
Maxwell Dee
Maxwell Dee
14 July 2026
Lumos Diagnostics has received a A$709,837 cash refund from the Australian Government’s R&D Tax Incentive, bolstering its investment in proprietary point-of-care diagnostic technologies.
Ada Torres
Ada Torres
29 June 2026

Browse the archive

Full archive